Fibrogen INC Form 4 insider transactions

Director Maykin Ho was granted 7,000 stock options in Kyntra Bio, Inc. as part of a standard equity compensation package.

Director Jeffrey L. Edwards was granted 7,000 stock options in Kyntra Bio, Inc. with an exercise price of $7.13.

Director Michael Kauffman was granted 7,000 stock options in Kyntra Bio, Inc. as part of a standard equity compensation plan.

Director James A. Schoeneck was granted 7,000 stock options in Kyntra Bio, Inc. as part of a standard equity compensation plan.

CEO Thane Wettig reported the withholding of 198 shares of Kyntra Bio common stock to satisfy tax obligations related to restricted stock unit vesting.

Kyntra Bio CFO David DeLucia disposed of 52 shares to satisfy tax obligations related to restricted stock unit vesting.

Kyntra Bio, Inc. CEO Thane Wettig filed an amended Form 4 to correct a previous reporting error regarding a stock purchase.

Thane Wettig, CEO and Director of Kyntra Bio, Inc., reported a transaction involving the acquisition of 2,800 shares of common stock.

KYNTRA BIO, INC. CEO and Director Thane Wettig was granted 60,000 stock options exercisable at $8.50 per share.

KYNTRA BIO, INC.'s Chief Financial Officer, David DeLucia, was granted 26,000 stock options with an exercise price of $8.5, vesting over four years.

FibroGen's Chief Financial Officer, David DeLucia, disposed of 52 shares of common stock to cover tax liabilities from vested restricted stock units.

FibroGen's CEO, Thane Wettig, disposed of 259 shares of common stock at $8.42 per share to cover tax obligations related to restricted stock unit vesting.

FibroGen CEO Thane Wettig acquired additional common stock in two separate transactions in November 2025, signaling increased confidence.

FibroGen's Chief Financial Officer, David DeLucia, reported the disposition of common stock to cover tax liabilities related to restricted stock unit vesting.

FibroGen CEO Thane Wettig reported routine, pre-planned dispositions of shares to cover tax obligations following restricted stock unit vesting, reflecting a recent 1-for-25 reverse stock split.

FibroGen Inc. Director James A. Schoeneck purchased 23,567 shares of common stock at a weighted-average price of $5.07 per share, increasing his indirect beneficial ownership to 39,666 shares after a 1-for-25 reverse stock split.

FibroGen Inc. Director Maykin Ho was granted 120,000 stock options with an exercise price of $0.3051, vesting over four equal quarterly installments or by the next annual meeting.

FibroGen Inc. Director Jeffrey L. Edwards was granted 120,000 stock options with an exercise price of $0.3051, vesting over four quarterly installments or by the next annual meeting.

FibroGen Inc. Director James A. Schoeneck was granted 120,000 stock options with an exercise price of $0.3051, vesting over four equal quarterly installments or by the next annual meeting.

FibroGen Inc. Director Michael Kauffman was granted stock options for a total of 190,000 shares of common stock on June 4, 2025, aligning his interests with shareholder value.

FibroGen's CEO, Thane Wettig, recently purchased 145,000 shares of the company's common stock at an average price of $0.3494 per share.

Director James A. Schoeneck reports purchasing FibroGen shares in multiple transactions, increasing his indirect holdings.

FibroGen CEO Thane Wettig reports the acquisition and disposal of company stock related to vesting of restricted stock units and PSU milestone grants.

Christine Chung, SVP of China Operations at FibroGen, reports the acquisition and disposal of company stock to cover tax obligations and vesting of restricted stock units.

David DeLucia, CFO of FibroGen, reports the disposal of 2,325 shares to cover tax obligations.

FibroGen's Chief Financial Officer, David DeLucia, was granted 525,000 stock options on January 9, 2025.

FibroGen's CEO, Thane Wettig, was granted 1.3 million stock options with a strike price of $0.6508, vesting quarterly over four years starting January 9, 2025.

FibroGen's Chief Financial Officer, Juan Graham, sold a total of 2,512 shares of common stock to cover tax obligations related to vesting restricted stock units.

FibroGen CEO Thane Wettig sold 2,363 shares of common stock to cover tax obligations related to vesting restricted stock units.

Christine Chung, SVP of China Operations at FibroGen, sold 2,792 shares of common stock to cover tax obligations related to vesting restricted stock units.